3 Results for "

siRNA therapeutics

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "siRNA therapeutics" in MCE Product Catalog:

Cat. No.: HY-184774
CAS No.: 1551528-06-3
Target:  

Drug Intermediate

Research Areas:  

Others

tri-GalNAc-C10-COOH (P290 232) is a targeted delivery intermediate composed of a trivalent N-acetylgalactosamine (GalNAc) cluster attached to a C10 linker ending with a carboxylic acid (-COOH) group. tri-GalNAc-C10-COOH is a standard building block used to synthesize LYTACs (lysosome-targeting chimeras) and cell-specific oligonucleotides like siRNA or ASO therapeutics .
loading...
    loading...
Cat. No.: HY-187478A
Synonyms: DOPE-PEG2000-Mal-Cys-LIRLWSHLIHIWFQNRRLKWKKK
Research Areas:  

Others

DOPE-PEG2000-EB1 (DOPE-PEG2000-Mal-Cys-LIRLWSHLIHIWFQNRRLKWKKK) is an amphiphilic lipid-PEG-peptide conjugate composed of DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), PEG2000, and the EB1 peptide (a penetratin analog). EB1 peptide is an endosomolytic agent that forms an amphipathic alpha helix upon protonation in endosomes, driving endosomal membrane permeabilization. DOPE-PEG2000-EB1 is used for intracellular delivery of nucleic acids (e.g., siRNA) and other macromolecular therapeutics.
loading...
    loading...
Cat. No.: HY-L251
93 compounds

Ionizable lipids are a class of specialized, functional lipid molecules with pH-sensitive charge characteristics. They are primarily divided into two major categories: ionizable cationic lipids and ionizable anionic lipids, though the term typically specifies ionizable cationic lipids within the biomedical field. Structurally, these lipids consist of an ionizable hydrophilic headgroup, a biodegradable linker, and hydrophobic tails. Their primary application is serving as the key delivery vehicle in lipid nanoparticles (LNPs) to encapsulate negatively charged nucleic acid macromolecules, such as mRNA vaccines, siRNA therapeutics, and CRISPR gene-editing components. In a physiological, neutral environment, they remain electrically neutral to minimize systemic toxicity and prolong circulation time. Upon entering the acidic microenvironment of cellular endosomes, however, they undergo protonation to become positively charged, thereby inducing membrane fusion and enabling the highly efficient intracellular release of the nucleic acid cargo. Consequently, they serve as the technological cornerstone for bringing nucleic acid therapies into clinical application.

To accelerate the translational process of cutting-edge nucleic acid drugs, MCE has meticulously constructed an ionizable lipid compound library containing 93 high-performance molecules, aiming to provide researchers and pharmaceutical professionals with a high-throughput, multi-dimensional lipid screening platform.